403
Sorry!!
Error! We're sorry, but the page you were
looking for doesn't exist.
Hypera Pharma Sacrifices Short-Term Profit For Long-Term Cash Flow Strength
(MENAFN- The Rio Times) Hypera Pharma reported a steep 74.2% drop in fourth-quarter profit from continuing operations, falling to R$79.5 million ($13.9 million) compared to the same period last year.
The pharmaceutical company's financial statement revealed these results stem from a strategic working capital optimization initiative. The company's EBITDA from continuing operations plunged 76.4% to R$136.9 million ($24 million) in Q4, with margins shrinking to 9.1%.
Revenue declined 18.2% to R$1.5 billion ($263.2 million) during the quarter. These drops reflect Hypera's deliberate reduction of inventory levels at clients. For the full year 2024, Hypera recorded net income of R$1.3 billion ($228.1 million), down 19.3% from 2023.
Annual EBITDA fell 23.8% to R$2.1 billion ($368.4 million), while revenue decreased 6% to R$7.4 billion ($1.3 billion). Despite these declining performance metrics, Hypera achieved record operating cash flow of R$2.539 billion ($445.4 million) in 2024, representing a 6% increase over 2023.
This highlight demonstrates the working capital initiative's effectiveness in generating immediate cash. Hypera's management explained the strategic shift began in the third quarter and intensified in the fourth.
Hypera 2024 Financial Results
The company deliberately reduced sales to decrease client inventory and subsequently reduce accounts receivable days. This approach prioritizes long-term financial stability over short-term profits.
The pharmaceutical giant maintained its marketing, R&D, and production capacity investments throughout 2024 despite the working capital optimization. These ongoing expenditures contributed to higher marketing, sales, and administrative expenses.
Hypera closed December 2024 with a net debt of R$7.5 billion ($1.32 billion), slightly higher than the R$7.4 billion ($1.3 billion) reported at the end of 2023. The company recorded a negative financial result of R$221.5 million for the quarter.
The working capital optimization represents a calculated approach expected to yield substantial benefits. Hypera projects it will generate potential cash flow increases of R$2.5 billion by 2028, with full benefits beginning to materialize in 2026.
The pharmaceutical company's financial statement revealed these results stem from a strategic working capital optimization initiative. The company's EBITDA from continuing operations plunged 76.4% to R$136.9 million ($24 million) in Q4, with margins shrinking to 9.1%.
Revenue declined 18.2% to R$1.5 billion ($263.2 million) during the quarter. These drops reflect Hypera's deliberate reduction of inventory levels at clients. For the full year 2024, Hypera recorded net income of R$1.3 billion ($228.1 million), down 19.3% from 2023.
Annual EBITDA fell 23.8% to R$2.1 billion ($368.4 million), while revenue decreased 6% to R$7.4 billion ($1.3 billion). Despite these declining performance metrics, Hypera achieved record operating cash flow of R$2.539 billion ($445.4 million) in 2024, representing a 6% increase over 2023.
This highlight demonstrates the working capital initiative's effectiveness in generating immediate cash. Hypera's management explained the strategic shift began in the third quarter and intensified in the fourth.
Hypera 2024 Financial Results
The company deliberately reduced sales to decrease client inventory and subsequently reduce accounts receivable days. This approach prioritizes long-term financial stability over short-term profits.
The pharmaceutical giant maintained its marketing, R&D, and production capacity investments throughout 2024 despite the working capital optimization. These ongoing expenditures contributed to higher marketing, sales, and administrative expenses.
Hypera closed December 2024 with a net debt of R$7.5 billion ($1.32 billion), slightly higher than the R$7.4 billion ($1.3 billion) reported at the end of 2023. The company recorded a negative financial result of R$221.5 million for the quarter.
The working capital optimization represents a calculated approach expected to yield substantial benefits. Hypera projects it will generate potential cash flow increases of R$2.5 billion by 2028, with full benefits beginning to materialize in 2026.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Most popular stories
More Story
Comments
No comment